Studies suggest that synthetic GHRP-2 may attach to the ghrelin/growth hormone secretagogue receptor and act as a secretagogue for growth hormone. Experimental studies suggest it may promote muscular development, control the immune system, and enhance sleep quality. 

What is GHRP-2 Peptide?

Research suggests synthetic GHRP-2 (Pralmorelin) may bind to the ghrelin/growth hormone secretagogue receptor. Findings imply that the potential impact of GHRP-2 on hunger, muscular development, the immune system, and sleep cycles is actively being studied, and it has been studied in stage II experimental research. 

GHRP-2 and Muscle Tissue

Yak studies suggest that GHRP-2 may promote muscle development via enhanced protein deposition and reduced protein breakdown. It was speculated that GHRP-2 may help yaks get through the development plateaus they experience naturally when faced with dietary restrictions, illness, or extreme temperatures. The most important takeaway from this research is that GHRP-2 is hypothesized to inhibit atrogin-1 and MuRF1, which regulate the muscle breakdown process, potentially reducing muscular atrophy. These speculations provide optimism that catabolism may be mitigated in chronic diseases such as autoimmune disorders, cancer, and others.

It has been purported that GHRP-2 may naturally aid in increasing muscle protein deposition by stimulating the secretion of growth hormone and insulin-like growth factor-1. Scientists speculate that GHRP-2 may promote the growth of lean body mass despite unfavorable environmental factors by possibly decreasing degradation and increasing deposition.

GHRP-2 Peptide and Hunger

Data from research studies suggests that GHRP-2 may increase hunger. Appetite stimulation in the context of chronic illness is a crucial component of comprehensive mitigation of disease consequences. Research suggests that the potential capacity to boost hunger consistently may be pivotal in managing chronic illnesses.

GHRP-2 Peptide and the Heart

In studies using fetal heart cell culture lines, GHRP-2 and its counterparts (GHRP-1 and GHRP-6) have been suggested to protect heart cells by decreasing apoptosis or programmed cell death. After a cardiac attack, heart cells are more vulnerable to apoptosis when blood flow and nutrients are cut off. Studies using the GHRP-2 counterpart Hexarelin suggest these peptides may have a dedicated receptor.

GHRP-2 Peptide and the Immune System

The thymus, an organ that helps keep certain immune cells safe, has been hypothesized to respond well to GHRP-2. The thymus plays an essential part in the development of mature T lymphocytes. When it comes to fighting off complicated infections and relying on adaptive immunity, T cells are considered to be essential. Inadequate tissue repair, loss of immunity, and the inability to fend off infections, protect against cancer, and preserve normal tissue function are some age-related dysfunctions resulting from the thymus’s declining activity. The quantity and variety of T cells produced by the thymus are speculated to be increased with GHRP-2. As a result, the immune system may strengthen.

GHRP-2 Peptide and Sleep

GHRP-2 has been suggested to boost REM sleep by around 20%, extend the length of stages 3 and 4 by about 50%, and decrease the degree to which a research model deviates from “normal sleep” by as much as 35%. Brain health, cardiovascular health, wound healing, and physical vitality were all hypothesized to be enhanced by better sleep. 

GHRP-2 Peptide and Pain Sensitivity 

It was initially believed that GHRP-2’s potential ability to increase growth hormone levels and speed up the repair of injured tissues may have been responsible for pain reduction in animal osteoarthritis models. While GHRP-2 may directly impact pain perception, astute scientists hypothesized that pain alleviation occurred before recovery. Through their research, they speculated that GHRP-2 may influence the function of opioid receptors.

Opioid receptors come in four different varieties. Most opioid substances act in the same way. This is troublesome because not all receptors have the same function; some regulate pain, others influence factors like wakefulness and respiration, and others affect addiction. In particular, studies suggest that GHRP-2 may bind to the opioid receptors that modulate pain, sedation, and addiction. Based on these outcomes, it may be attainable to develop selective opioid agonists, which might reduce or eliminate potentially unwanted effects, including respiratory depression and addiction.

Core Peptides sells GHRP-2 only for use in academic and scientific research, not for human consumption. You must be a legitimate scientist to purchase GHRP-2. The research compounds mentioned in this article should only be used in contained research environments such as laboratories. Any bodily introduction is prohibited by law.

References

[i] R. Hu et al., “Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation,” PloS One, vol. 11, no. 2, p. e0149461, 2016. [PLOS ONE]

[ii] D. Yamamoto et al., “GHRP-2, a GHS-R agonist, directly acts on myocytes to attenuate the dexamethasone-induced expressions of muscle-specific ubiquitin ligases, Atrogin-1 and MuRF1,” Life Sci., vol. 82, no. 9–10, pp. 460–466, Feb. 2008. [PubMed]

[iii] L. T. Phung et al., “The effects of growth hormone-releasing peptide-2 (GHRP-2) on the release of growth hormone and growth performance in swine,” Domest. Anim. Endocrinol., vol. 18, no. 3, pp. 279–291, Apr. 2000. [PubMed]

[iv] B. Laferrère, C. Abraham, C. D. Russell, and C. Y. Bowers, “Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men,” J. Clin. Endocrinol. Metab., vol. 90, no. 2, pp. 611–614, Feb. 2005. [PubMed]

[v] B. Laferrère, A. B. Hart, and C. Y. Bowers, “Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake,” Obes. Silver Spring Md, vol. 14, no. 6, pp. 1056–1063, Jun. 2006. [PMC]

[vi] G. Muccioli et al., “Growth hormone-releasing peptides and the cardiovascular system,” Ann. Endocrinol., vol. 61, no. 1, pp. 27–31, Feb. 2000. [PubMed

[vii] V. Bodart et al., “Identification and characterization of a new growth hormone-releasing peptide receptor in the heart,” Circ. Res., vol. 85, no. 9, pp. 796–802, Oct. 1999. [AHA Journals]

[viii] D. D. Taub, W. J. Murphy, and D. L. Longo, “Rejuvenation of the aging thymus: growth hormone-mediated and ghrelin-mediated signaling pathways,” Curr. Opin. Pharmacol., vol. 10, no. 4, pp. 408–424, Aug. 2010. [PubMed]

[ix] G. Copinschi et al., “Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man,” Neuroendocrinology, vol. 66, no. 4, pp. 278– 286, Oct. 1997. [PubMed]

[x] P. Zeng et al., “Ghrelin receptor agonist, GHRP-2, produces antinociceptive effects at the supraspinal level via the opioid receptor in mice,” Peptides, vol. 55, pp. 103–109, May 2014. [PubMed]